Program
MK-1167
A development code.
Its studies are mostly in Alzheimer Disease, led by Merck.
Furthest: phase 2, since Dec 3, 20246 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 60 open or running | phase 2since Dec 3, 2024 | Feb 22, 2024 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 22, 2024First study: phase 1 study in Alzheimer DiseaseFirst studyNCT06285240 · 28 enrolled · United States
- Oct 1, 2024Phase 1 study in HealthyNCT06625840 · 16 enrolled · United States
- Nov 21, 2024Phase 1 study in HealthyNCT06703463 · 16 enrolled · United States
- Dec 3, 2024Phase 2 study in Alzheimer DiseaseNCT06721156 · 369 enrolled · United States, Argentina, Canada and more
- Dec 1, 20252 phase 1 studies in HealthyNCT07266818, NCT07334860
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07334860Healthy · United States | 1 | Completed | May 20, 2026 | 16 |
| NCT07266818Healthy · United States | 1 | Completed | Apr 9, 2026 | 30 |
| NCT06721156Alzheimer Disease · United States, Argentina, Canada and more | 2 | Terminated | Jun 5, 2026 | 369 |
| NCT06703463Healthy · United States | 1 | Completed | Feb 2, 2024 | 16 |
| NCT06625840Healthy · United States | 1 | Completed | May 8, 2024 | 16 |
| NCT06285240Alzheimer Disease · United States | 1 | Completed | Sep 23, 2024 | 28 |
How it is read
Names in the registry
- “MK-1167”, 6 entries
Codes read as this program: MK1167.
Conditions, from the studies’ own filings
- Alzheimer Disease, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.